Semler Scientific Announces Pricing of Initial Public Offering of Common Stock
PORTLAND, Ore., Feb. 20, 2014 /PRNewswire/ — Semler Scientific, Inc. (NASDAQ: SMLR), an emerging medical risk-assessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today announced the pricing of its initial public offering of 1,430,000 shares of its common stock at an initial public offering price of $7.00 per share. The gross proceeds to Semler from the initial public offering are expected to be $10,010,000, before underwriting discounts and commissions and other offering expenses. In addition, Semler has granted the underwriters a 45-day option to purchase up to 214,500 additional shares of common stock from Semler to cover over-allotments, if any. Semler’s common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading under the symbol “SMLR” on February 21, 2014.
The offering is expected to close on February 26, 2014, subject to customary closing conditions.
Aegis Capital Corp. is acting as sole book-running manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 20, 2014. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, via telephone: 212-813-1010, or via e-mail: email@example.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Semler Scientific, Inc.:
Semler Scientific, Inc. is an emerging medical risk-assessment company. Its mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services. Semler’s first patented and U.S. Food and Drug Administration, or FDA, cleared product, is FloChec(TM). FloChec(TM) is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a useful tool for internists and primary care physicians for whom it was previously impractical to conduct blood flow measurements. FloChec(TM) received FDA 510(k) clearance in February 2010, Semler began Beta testing in the third quarter of 2010, and Semler began commercially leasing FloChec(TM) in January 2011.
Susan A. Noonan
S.A. Noonan Communications
212 966 3650
SOURCE Semler Scientific, Inc.